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Abstract
Surgical resection is the gold standard for hepatocellular carcinoma manage-
ment for early stages of the disease. With advances in technology and techniques, 
minimally invasive surgery provides a great number of advantages for these patients 
during their surgery and for their post-operative care. The selection of patients fol-
lowing a multi-disciplinary approach is of paramount importance. Adding to this, 
the developments in laparoscopic instruments and training, as well as the promising 
advantages of robotic surgery along with other forms of technology, increase the 
pool of patients that can undergo operation safely and with good results worldwide. 
We review results from great centres worldwide and delineate the accurate multi-
disciplinary approach for this.
Keywords: laparoscopic, robotic, minimally invasive surgery, hepatocellular 
carcinoma
1. Introduction
Liver cancer is the 5th most common cancer and the second most frequent cause 
of cancer-related death globally, with 854,000 new diagnoses and 810,000 deaths 
per year [1, 2]. Hepatocellular carcinoma (HCC) accounts for approximately 90% 
of liver cancers and is generally associated with an unfavorable prognosis, with a 
5-year overall survival (OS) of 10–15%, mostly due to a delay in establishing an 
early diagnosis. In case HCC is diagnosed at an earlier stage, the 5-year OS improves 
and may reach 70%, amid the possibility of curative treatments, such as liver resec-
tion (LR), liver transplantation (LT) and ablation [3, 4].
2. Minimally invasive surgery for HCC
2.1 Staging systems and treatment allocation
Once diagnosed, prognostication is pivotal in the management of HCC. Disease 
staging and classification is intended to assess prognosis and determine treatment 
candidacy. In patients with HCC, the co-existence of two life-threatening condi-
tions, i.e., cancer and cirrhosis, needs to be tackled with, and further complicates 
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prognostic assessment [5, 6]. The 2018 European Association for the Study of 
the Liver (EASL) clinical practice guidelines endorsed the Barcelona Clinic Liver 
Cancer (BCLC) classification [7], as did the recent American Association for the 
Study of Liver Diseases (AASLD) guidance [3]. According to the BCLC classifica-
tion system, patients are classified into five stages (0, A, B, C and D) according to 
pre-established prognostic variables. These variables comprise tumor characteris-
tics (size, number, vascular invasion, lymph node involvement, distant metastases), 
liver function (bilirubin, portal hypertension, liver function preservation) and 
patient’s health status (ECOG).
2.2 Liver resection
Determining eligibility for LR involves assessment of the tumor burden; assess-
ment of liver function; the extent of hepatectomy and the expected volume of the 
future liver remnant; and the presence of portal hypertension and other co-morbid-
ities. Liver function is objectively estimated by the Child-Pugh score and patients 
with Child-Pugh B or C are deemed at a high risk of liver failure following LR, 
even after a minor resection. More recently, the model for end-stage liver disease 
(MELD) score was integrated into the EASL guidelines for treatment allocation 
[7, 8]. The absence of cirrhosis allows for larger and more complex resections, and 
is associated with viable postoperative mortality and morbidity, even after major 
hepatic resection, with a 5-year OS of 50% [9–13]. Conversely, clinically significant 
portal hypertension (CSPH), defined as HVPG >10 mmHg, is a well-established 
predictor of liver decompensation and death after LR [14–18].
Surgery represents the backbone of HCC treatment, resulting in the best 
outcomes in appropriately-selected candidates. LR and LT represent the first-line 
treatment in individuals with early-stage tumors on an intention-to-cure perspec-
tive. In particular, the latest EASL guidance recommends LR in cases of a resectable 
solitary nodule without macrovascular invasion and extrahepatic spread, regardless 
of size [7, 19]. The AASLD guidelines advocate LR in patients with Child-Pugh 
A compensated cirrhosis and resectable HCC, i.e., solitary tumor <5 cm with or 
without vascular invasion, or multifocal tumor <5 cm [3]. Finally, the Asian Pacific 
Association for the Study of the Liver (APASL) recommends that all tumors with-
out extrahepatic spread may be considered for LR, regardless of vascular invasion, 
number and size of lesions [4].
2.3 A laparoscopic approach
The advent of laparoscopic techniques transformed the treatment landscape of 
HCC. In spite of the relative paucity of prospective randomized studies, the lapa-
roscopic approach appears to convey similar oncological outcomes with respect to 
conventional surgery [20]. Laparoscopic LR allows the preservation of the abdomi-
nal wall, minimizes peritoneal trauma, and is associated with fewer complications 
in comparison with open surgery, including both overall and liver-related complica-
tions, as also shown in a recent meta-analysis including 6,812 patients. Additionally, 
no differences in operative time, blood loss, intraoperative complications, hospital 
stay, and morbidity were found in laparoscopic LR for cirrhotics in comparison 
with non-cirrhotics [21–28]. Several studies demonstrated that minimally-invasive 
surgical techniques in patients with cirrhosis are associated with reduced risk of 
post-operative hepatic decompensation and liver failure [29–31]. Interestingly, 
this technique also appears safe in the elderly, even for a major hepatectomy, and is 
associated with improved outcomes [32–36]. One should bear in mind though that 
laparoscopic hepatectomy should be carried out in specialist centres and following 
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appropriate training and education of all team members involved. The importance 
of this factor is highlighted as the keys to successful LR include technical master-
ing of laparoscopic hepatic portal occlusion which can be more challenging than 
in laparotomy, and the lack of operational feel and need for rapid reactive mode as 
well as accurate hemostasis.
In light of the above, EASL 2018 clinical practice guidelines recommend laparo-
scopic LR for HCC resection in expert centres and for selected surgical candidates 
[7]. Similarly, the AASLD also recognizes the advantages of laparoscopic techniques 
in selected scenarios [3]. EASL recommends [7] that tumor size and location should 
determine optimal surgical approach. In particular, laparoscopic-robotic LR for 
HCC may be considered for tumors located in superficial peripheral positions of 
the liver; and is associated with optimal survival outcomes, low complication rate 
and reduced inpatient time. Minimally-invasive LR can be an effective option in 
very early (≤2 cm) and early HCC. Ablation represents still the treatment modality 
of choice for this disease stage, owing to the higher cost-effectiveness [16] and to 
milder liver function impact. However, several studies report that patients treated 
with minimally-invasive LR for such tumors, mainly located in superficial or 
antero-lateral positions, suffer less adverse outcomes and shorter hospitalization, 
in comparison with conventional open techniques, while achieving competitive 
oncologic results with respect to ablation [37–40].
Limited resections conducted via laparoscopic LR may also be considered for 
curative resection in selected patients with HCC with a borderline liver profile (i.e., 
Child Pugh B7, moderate portal hypertension and/or bilirubin around 2 mg/dl), 
especially in specialized centres [7]. A study reported that patients with Child-Pugh 
A and Child-Pugh B/C cirrhosis who underwent laparoscopic LR had a similar 
perioperative course [26]. Laparoscopic LR has also been explored as an option for 
patients with CSPH. A recent study by Lim et al assessed the short-term outcomes 
in patients with and without CSPH [41]. Although broadening eligibility criteria for 
minimally-invasive techniques would increase the rate LR, morbidity and hospital 
stay would be a significant concern for patients with CSPH. In light of the above, LT 
remains the gold standard in cases of HCC and advanced liver disease. Nevertheless, 
the laparoscopic approach may be beneficial prior to LT for HCC, with significantly 
reduced de-listing and death after LT when prior LR was performed laparoscopi-
cally [42]. Whether laparoscopic LR should also be considered in patients with HCC 
and CSPH not eligible for LT, will need to be addressed with further studies. Lastly, 
the safety and feasibility of laparoscopic major hepatectomy has been reported after 
sequential transarterial chemoembolization (TACE), which is classically associated 
with increased surgical difficulty [43]. Additionally, laparoscopic LR can be applied 
in living donor liver transplantation (LDLT) in centres with extensive experience in 
both laparoscopic LR and open LDLT.
2.4 Robotic liver surgery
Similar to laparoscopic LR, robotic LR is also emerging as an interesting mini-
mally-invasive surgical technique, demonstrating a relative safe profile and allow-
ing for an easier access to hepatic segments not amenable to laparoscopic approach, 
such as posterior sectionectomies and resection of tumors located in superior 
segments 4a and 8 [44]. The development of minimally invasive surgical techniques 
for liver tumors is in general limited by the characteristics of the liver itself, such as 
its texture, abundant blood supply, an increased number of structural variations of 
blood vessels and bile ducts.
A recent literature review including 10 studies on robotic liver resection for 
HCC (with a total of 302 patients) reported disease-free (DFS) and OS at 2 years 
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of 72–84% and 94–98%, respectively [44]. It has also been proposed that a robotic 
approach may also improve the access to the abdomen in cases of recurrent disease 
with potential requirement of LT, expanding the opportunities of both down-stag-
ing and bridging strategies [45]. The broad use of the robotic approach, however, 
is limited due to several factors, most importantly the cost of the robotic surgical 
devices compared to laparoscopic equipment. Several analyses on costs of robotic 
surgery have been reported, with controversial findings regarding the balance 
between costs and benefits [46–51]. With regard to instrumentation, the lack of an 
efficient robotic transection device such as the Ultasonographic Aspirator (UA) is 
the most important limitation of robotic liver surgery. Another limitation would be 
the spatial distance between the operating and robotic platform and its considerable 
size, making undocking and gaining access to the patient particularly challenging in 
emergency scenarios [52, 53]. Lastly, a non-negligible obstacle of robotic surgery is 
the operative time, that is in the majority longer in comparison with other surgical 
approaches. In view of the above, robotic LR needs to be better evaluated before 
being integrated into routine clinical practice and therapeutic algorithms. On the 
other hand, however, robotic LR can overcome certain traditional laparoscopic liver 
resection limitations like the inflexible fixation of the operating instruments as well 
as visual result [54]. The Robotic System appears superior in regard to these limita-
tions and there are constant developments in the field as per instruments applied 
crucial to LR. At present, the Da Vinci Robotic surgical assistant system is in use 
in several centres for both benign and malignant liver diseases with similar indica-
tions applied as per the laparoscopic LR, and in certain cases demonstrating a more 
advantageous nature [55].
2.5 Cost of minimally invasive surgery
The results so far comparing robotic to laparoscopic and open LR are conflicting 
as per the cost effect to the institution hosting them. A single institution retrospec-
tive study from the University of Washington compared cost data for 71 robotic LR 
to 88 open procedures and reported that although there were higher perioperative 
costs for the robotic procedures, the postoperative costs and subsequent direct 
hospital costs were lower when compared with open procedures, attributing this 
possibly to a 2-day shorter hospital stay on average after robotic procedures [56]. On 
the other hand other studies have demonstrated a higher cost for robotic LR when 
compared to both laparoscopic and open procedures although in some the trend of 
less hospital stay was in favor of the robotic procedures [57–59].
2.6 Emerging technologies
Recent advances in liver surgery from a technological aspect include near-
infrared fluorescent (NIF) imaging applied intra-operatively. NIF imaging has 
been set in use in several laparoscopic and robotic camera systems enabling the 
identification of various dyes, such as indocyanine green, injected preoperatively. 
Indocyanine green is a green dye that is preferentially metabolized by hepatocytes 
and excreted in the biliary tree and it lights up the biliary tree. Its use has been 
utilized for robotic and laparoscopic assisted cholecystectomy. It has also been more 
recently applied for a more accurate parenchymal dissection following vascular 
control by identifying perfused from poorly perfused hepatic parenchyma [60].
Future advances of robotic liver surgery include the application of preoperative 
planning with virtual reality (VR) models and real-time augmented reality (AR) 
intra- operative endoscopic overlays to assist with surgical navigation on da Vinci 
® surgical systems. Computer-based three-dimensional (3D) reconstructions of 
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liver tumors have been shown to benefit the accuracy of tumor localization and 
precision of operative planning for liver surgery [61, 62]. Intraoperative Ultrasound 
is routinely used for real-time identification of liver tumors both in open and 
minimally invasive LR. However, with AR being developed to overlay accurate 3D 
reconstruction data onto the operative field itself, it can potentially eliminate the 
need to divert the attention from the operative field and to translate the 2D images 
into a 3D construct.
3. Conclusions
With the constant evolution of technology, it would be without a doubt that 
surgery techniques in terms of access and instrument implementation would evolve 
as well. Laparoscopic liver surgery appears to have gained considerable ground 
especially in centres where liver surgery and laparoscopic expertise co-exist. The 
robotic approach is still quite variable between institutions, as well as between 
countries and continents. Thus one can only anticipate for advances in minimally 
invasive surgery to continue as long as there are specialized liver centres aiming to 
increase patient volume undergoing surgery and decrease hospital stay, complica-
tions rates and in general offer the best possible liver service.
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